Athira Sethu
Kochi, 10 Feb 2026
Leading pharmaceutical firm, Lupin, has entered into a settlement deal with another firm, Astellas Pharma, on the dispute pertaining to a patent for its medicine, Mirabegron. As a result of the agreement, Lupin is to settle the dispute by paying a total of $90 million to Astellas Pharma.
Lupin and its U.S. subsidiary, Lupin Pharmaceuticals, Inc., have entered into an agreement with Astellas and its affiliates, including Astellas Pharma, Inc. and Astellas Pharma Global Development, Inc., as per a statement made on Tuesday. This deal also includes an upfront payment of $75 million as well as additional fees for every unit of Mirabegron sold by Lupin in the U.S. until September 2027.
The financial and commercial terms of this deal are not disclosed, but Lupin stated that this deal puts an end to the ongoing patent dispute between both companies.
In settling this case, Lupin will be able to continue trading its Mirabegron in the U.S. markets without any legal issues. This is vital for Lupin because this helps settle a major legal problem that they are currently having with their drug.
Lupin faced the issue of the patent infringement and announced it in April 2025. The company has gained more clarity about the future course and sales of Mirabegron, which is used as an overactive bladder drug.
The $90 million will be represented by the initial $75 million payment and the license fees, and will be paid based on the sales of the product in the United States for the next several years. This settlement will allow Lupin to continue with the marketing of Mirabegron with no hindrance from the ongoing legal case.
Overall, the settlement enables Lupin to solely focus on the business success of Mirabegron while resolving the lawsuit that potentially could have hindered the sale of the drug.
